KOREA WHO

Jung Hyun-ho is the CEO of Medytox.

He successfully developed Korea’s first botulinum toxin product, transforming Medytox into a specialized botulinum toxin company.

He was born on December 24, 1962, in Gwangju.

He majored in microbiology at Seoul National University and earned a master’s degree in cell biology and a doctorate in molecular biology from KAIST (Korea Advanced Institute of Science and Technology).

He worked as an invited researcher at the U.S. National Institutes of Health (NIH) and as a senior researcher at the Korea Research Institute of Bioscience and Biotechnology. He also served as an associate professor in the Department of Applied Biology at Sun Moon University.

In 2000, he founded Medytox and succeeded in developing the country’s first, and the world’s fourth, type A botulinum toxin product.

He has served as an Entrepreneurship Ambassador at the Chungbuk Center for Creative Economy and Innovation under the Ministry of Science, ICT and Future Planning, and as an advisor to the National Science and Technology Advisory Council.

He is the first person in Korea to earn a doctoral degree for research on botulinum toxin.

He is currently involved in strain-related lawsuits over botulinum toxin with Daewoong Pharmaceutical and Hugel.

#Medytox #JungHyunHo #botulinumtoxin #biotechnology #Korea #pharmaceuticals #molecularbiology #KAIST #NIH #intellectualproperty